1	The	The	B-NP	DT	O	4	NMOD	-1
2	in	in	I-NP	FW	O	3	AMOD	-1
3	vivo	vivo	I-NP	FW	O	4	NMOD	-1
4	properties	property	I-NP	NNS	O	11	NMOD	0
5	of	of	B-PP	IN	O	4	NMOD	-1
6	STX243	STX243	B-NP	NN	B-protein	5	PMOD	-1
7	:	:	O	:	O	4	P	-1
8	a	a	B-NP	DT	O	11	NMOD	-1
9	potent	potent	I-NP	JJ	O	11	NMOD	-1
10	angiogenesis	angiogenesis	I-NP	NN	O	11	NMOD	3	angiogenesis
11	inhibitor	inhibitor	I-NP	NN	O	0	ROOT	0
12	in	in	B-PP	IN	O	11	NMOD	-1
13	breast	breast	B-NP	NN	O	14	NMOD	-1
14	cancer	cancer	I-NP	NN	O	12	PMOD	-1
15	.	.	O	.	O	11	P	-1

1	The	The	B-NP	DT	O	4	NMOD	-1
2	steroidal-based	steroidal-based	I-NP	JJ	O	4	NMOD	-1
3	drug	drug	I-NP	NN	O	4	NMOD	-1
4	2-ethyloestradiol-3	2-ethyloestradiol-3	I-NP	NN	O	12	SUB	-1
5	,	,	O	,	O	12	P	-1
6	17-O	17-O	B-NP	NN	O	12	SUB	-1
7	,	,	O	,	O	12	P	-1
8	O-bis-sulphamate	O-bis-sulphamate	B-NP	NN	O	12	SUB	-1
9	(	(	O	(	O	11	DEP	-1
10	STX243	STX243	B-NP	NN	O	11	DEP	-1
11	)	)	O	)	O	8	NMOD	-1
12	has	have	B-VP	VBZ	O	0	ROOT	-1
13	been	be	I-VP	VBN	O	12	VC	-1
14	developed	develop	I-VP	VBN	O	13	VC	0
15	as	as	B-PP	IN	O	14	VMOD	-1
16	a	a	B-NP	DT	O	21	NMOD	-1
17	potent	potent	I-NP	JJ	O	21	NMOD	-1
18	antiangiogenic	antiangiogenic	I-NP	JJ	O	21	NMOD	3	angiogenic
19	and	and	I-NP	CC	O	21	NMOD	-1
20	antitumour	antitumour	I-NP	JJ	O	21	NMOD	-1
21	compound	compound	I-NP	NN	O	15	PMOD	-1
22	.	.	O	.	O	12	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	objective	objective	I-NP	NN	O	6	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	this	this	B-NP	DT	O	5	NMOD	-1
5	study	study	I-NP	NN	O	3	PMOD	-1
6	was	be	B-VP	VBD	O	0	ROOT	-1
7	to	to	B-VP	TO	O	8	VMOD	-1
8	ascertain	ascertain	I-VP	VB	O	6	PRD	-1
9	whether	whether	B-SBAR	IN	O	8	VMOD	-1
10	STX243	STX243	B-NP	NN	B-protein	11	SUB	-1
11	is	be	B-VP	VBZ	O	9	SBAR	-1
12	more	more	B-ADJP	RBR	O	13	AMOD	-1
13	active	active	I-ADJP	JJ	O	11	PRD	-1
14	in	in	B-ADVP	FW	O	13	AMOD	-1
15	vivo	vivo	I-ADVP	FW	O	14	AMOD	-1
16	than	than	B-PP	IN	O	13	AMOD	-1
17	the	the	B-NP	DT	O	21	NMOD	-1
18	clinically	clinically	I-NP	RB	O	19	AMOD	-1
19	relevant	relevant	I-NP	JJ	O	21	NMOD	-1
20	drug	drug	I-NP	NN	O	21	NMOD	-1
21	2-methoxyoestradiol	2-methoxyoestradiol	I-NP	NN	O	16	PMOD	-1
22	(	(	O	(	O	24	DEP	-1
23	2-MeOE2	2-MeOE2	B-NP	NN	O	24	DEP	-1
24	)	)	O	)	O	21	NMOD	-1
25	and	and	O	CC	O	21	NMOD	-1
26	the	the	B-NP	DT	O	30	NMOD	-1
27	structurally	structurally	I-NP	RB	O	28	AMOD	-1
28	similar	similar	I-NP	JJ	O	30	NMOD	-1
29	compound	compound	I-NP	NN	O	30	NMOD	-1
30	2-MeOE2-3	2-MeOE2-3	I-NP	NN	O	32	NMOD	-1
31	,	,	O	,	O	32	P	-1
32	17-O	17-O	B-NP	NN	O	25	PMOD	-1
33	,	,	O	,	O	34	P	-1
34	O-bis-sulphamate	O-bis-sulphamate	B-NP	NN	O	32	NMOD	-1
35	(	(	O	(	O	37	DEP	-1
36	STX140	STX140	B-NP	NN	B-protein	37	DEP	-1
37	)	)	O	)	O	34	NMOD	-1
38	.	.	O	.	O	6	P	-1

1	The	The	B-NP	DT	O	5	NMOD	-1
2	tumour	tumour	I-NP	NN	O	5	NMOD	-1
3	growth	growth	I-NP	NN	O	5	NMOD	4	growth
4	inhibition	inhibition	I-NP	NN	O	5	NMOD	18	inhibition
5	efficacy	efficacy	I-NP	NN	O	10	NMOD	0
6	,	,	O	,	O	10	P	-1
7	antiangiogenic	antiangiogenic	B-NP	JJ	O	8	NMOD	3	angiogenic
8	potential	potential	I-NP	NN	O	10	NMOD	18	potential
9	and	and	O	CC	O	10	NMOD	-1
10	pharmacokinetics	pharmacokinetic	B-NP	NNS	O	13	SUB	-1
11	of	of	B-PP	IN	O	10	NMOD	-1
12	STX243	STX243	B-NP	NN	B-protein	11	PMOD	-1
13	were	be	B-VP	VBD	O	0	ROOT	-1
14	examined	examine	I-VP	VBN	O	13	VC	-1
15	using	use	B-VP	VBG	O	14	VMOD	-1
16	four	four	B-NP	CD	O	19	NMOD	-1
17	in	in	I-NP	FW	O	18	AMOD	-1
18	vivo	vivo	I-NP	FW	O	19	NMOD	-1
19	models	model	I-NP	NNS	O	15	OBJ	-1
20	.	.	O	.	O	13	P	-1

1	Both	Both	O	CC	O	4	NMOD	-1
2	STX243	STX243	B-NP	NN	B-protein	4	NMOD	-1
3	and	and	I-NP	CC	O	4	NMOD	-1
4	STX140	STX140	I-NP	NN	B-protein	5	SUB	-1
5	were	be	B-VP	VBD	O	0	ROOT	-1
6	capable	capable	B-ADJP	JJ	O	5	PRD	-1
7	of	of	B-PP	IN	O	6	AMOD	-1
8	retarding	retard	B-VP	VBG	O	7	PMOD	18	retarding
9	the	the	B-NP	DT	O	10	NMOD	-1
10	growth	growth	I-NP	NN	O	8	OBJ	4	growth
11	of	of	B-PP	IN	O	10	NMOD	-1
12	MDA-MB-231	MDA-MB-231	B-NP	NN	O	14	NMOD	-1
13	xenograft	xenograft	I-NP	NN	O	14	NMOD	-1
14	tumours	tumour	I-NP	NNS	O	11	PMOD	-1
15	(	(	O	(	O	22	DEP	-1
16	72	72	B-NP	CD	O	18	AMOD	-1
17	and	and	I-NP	CC	O	18	AMOD	-1
18	63	63	I-NP	CD	O	19	NMOD	-1
19	%	%	I-NP	NN	O	22	DEP	-1
20	,	,	O	,	O	19	P	-1
21	respectively	respectively	B-ADVP	RB	O	19	NMOD	-1
22	)	)	O	)	O	14	NMOD	-1
23	,	,	O	,	O	5	P	-1
24	whereas	whereas	O	IN	O	5	VMOD	-1
25	no	no	B-NP	DT	O	26	NMOD	-1
26	inhibition	inhibition	I-NP	NN	O	27	SUB	0
27	was	be	B-VP	VBD	O	24	SBAR	-1
28	observed	observe	I-VP	VBN	O	27	VC	0
29	for	for	B-PP	IN	O	28	VMOD	-1
30	animals	animal	B-NP	NNS	O	29	PMOD	-1
31	treated	treat	B-VP	VBN	O	30	NMOD	19	treated
32	with	with	B-PP	IN	O	31	VMOD	-1
33	2-MeOE2	2-MeOE2	B-NP	NN	O	32	PMOD	-1
34	.	.	O	.	O	5	P	-1

1	Further	Further	B-NP	JJ	O	4	NMOD	-1
2	tumour	tumour	I-NP	NN	O	4	NMOD	-1
3	inhibition	inhibition	I-NP	NN	O	4	NMOD	18	inhibition
4	studies	study	I-NP	NNS	O	5	SUB	-1
5	showed	show	B-VP	VBD	O	0	ROOT	-1
6	that	that	B-SBAR	IN	O	5	VMOD	-1
7	STX243	STX243	B-NP	NN	B-protein	8	SUB	-1
8	was	be	B-VP	VBD	O	6	SBAR	-1
9	also	also	B-ADVP	RB	O	8	VMOD	-1
10	active	active	B-ADJP	JJ	O	8	PRD	-1
11	against	against	B-PP	IN	O	10	AMOD	0
12	MCF-7	MCF-7	B-NP	NN	B-protein	14	NMOD	-1
13	paclitaxel-resistant	paclitaxel-resistant	I-NP	JJ	O	14	NMOD	-1
14	tumours	tumour	I-NP	NNS	O	11	PMOD	-1
15	.	.	O	.	O	5	P	-1

1	Using	Use	B-VP	VBG	O	10	VMOD	-1
2	a	a	B-NP	DT	O	5	NMOD	-1
3	Matrigel	Matrigel	I-NP	NNP	O	5	NMOD	-1
4	plug-based	plug-based	I-NP	JJ	O	5	NMOD	-1
5	model	model	I-NP	NN	O	1	OBJ	-1
6	,	,	O	,	O	10	P	-1
7	in	in	B-NP	FW	O	8	AMOD	-1
8	vivo	vivo	I-NP	FW	O	9	NMOD	-1
9	angiogenesis	angiogenesis	I-NP	NN	O	10	SUB	3	angiogenesis
10	was	be	B-VP	VBD	O	0	ROOT	-1
11	restricted	restrict	I-VP	VBN	O	10	VC	18	restricted
12	with	with	B-PP	IN	O	11	VMOD	-1
13	STX243	STX243	B-NP	NN	B-protein	15	NMOD	-1
14	and	and	I-NP	CC	O	15	NMOD	-1
15	STX140	STX140	I-NP	NN	O	12	PMOD	-1
16	(	(	O	(	O	15	NMOD	-1
17	50	50	B-NP	CD	O	19	AMOD	-1
18	and	and	I-NP	CC	O	19	AMOD	-1
19	72	72	I-NP	CD	O	20	NMOD	-1
20	%	%	I-NP	NN	O	16	PMOD	-1
21	,	,	O	,	O	20	P	-1
22	respectively	respectively	B-ADVP	RB	O	20	NMOD	-1
23	,	,	O	,	O	20	P	-1
24	using	use	B-VP	VBG	O	20	NMOD	-1
25	a	a	B-NP	DT	O	28	NMOD	-1
26	10	10	I-NP	CD	O	27	AMOD	-1
27	mg	mg	I-NP	NN	O	28	NMOD	-1
28	kg	kg	I-NP	NN	O	24	OBJ	-1
29	(	(	O	(	O	34	DEP	-1
30	-1	-1	B-NP	CD	O	33	NMOD	-1
31	)	)	O	)	O	33	NMOD	-1
32	oral	oral	B-NP	JJ	O	33	NMOD	-1
33	dose	dose	I-NP	NN	O	34	DEP	-1
34	)	)	O	)	O	28	NMOD	-1
35	,	,	O	,	O	24	P	-1
36	thereby	thereby	B-VP	RB	O	37	VMOD	-1
37	showing	show	I-VP	VBG	O	24	VMOD	-1
38	the	the	B-NP	DT	O	40	NMOD	-1
39	antiangiogenic	antiangiogenic	I-NP	JJ	O	40	NMOD	3	angiogenic
40	activity	activity	I-NP	NN	O	37	OBJ	18	activity
41	of	of	B-PP	IN	O	40	NMOD	-1
42	both	both	B-NP	DT	O	43	NMOD	-1
43	compounds	compound	I-NP	NNS	O	41	PMOD	-1
44	.	.	O	.	O	10	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	pharmacokinetics	pharmacokinetic	I-NP	NNS	O	5	SUB	-1
3	of	of	B-PP	IN	O	2	NMOD	-1
4	STX243	STX243	B-NP	NN	B-protein	3	PMOD	-1
5	were	be	B-VP	VBD	O	0	ROOT	-1
6	examined	examine	I-VP	VBN	O	5	VC	-1
7	at	at	B-PP	IN	O	6	VMOD	-1
8	two	two	B-NP	CD	O	10	NMOD	-1
9	different	different	I-NP	JJ	O	10	NMOD	-1
10	doses	dose	I-NP	NNS	O	7	PMOD	-1
11	using	use	B-VP	VBG	O	5	VMOD	-1
12	adult	adult	B-NP	JJ	O	14	NMOD	-1
13	female	female	I-NP	JJ	O	14	NMOD	-1
14	rats	rat	I-NP	NNS	O	11	OBJ	-1
15	.	.	O	.	O	5	P	-1

1	The	The	B-NP	DT	O	2	NMOD	-1
2	compound	compound	I-NP	NN	O	3	SUB	-1
3	was	be	B-VP	VBD	O	0	ROOT	-1
4	orally	orally	B-ADJP	RB	O	3	VMOD	-1
5	bioavailable	bioavailable	I-ADJP	JJ	O	21	AMOD	-1
6	(	(	O	(	O	19	DEP	-1
7	31	31	B-NP	CD	O	8	NMOD	-1
8	%	%	I-NP	NN	O	19	DEP	-1
9	after	after	B-PP	IN	O	8	NMOD	-1
10	a	a	B-NP	DT	O	14	NMOD	-1
11	single	single	I-NP	JJ	O	13	AMOD	-1
12	10	10	I-NP	CD	O	13	AMOD	-1
13	mg	mg	I-NP	NN	O	14	NMOD	-1
14	kg	kg	I-NP	NN	O	9	PMOD	-1
15	(	(	O	(	O	17	DEP	-1
16	-1	-1	B-NP	CD	O	17	DEP	-1
17	)	)	O	)	O	14	NMOD	-1
18	dose	dose	B-NP	NN	O	14	NMOD	-1
19	)	)	O	)	O	5	AMOD	-1
20	and	and	O	CC	O	21	AMOD	-1
21	resistant	resistant	B-ADJP	JJ	O	3	VMOD	-1
22	to	to	B-PP	TO	O	21	AMOD	-1
23	metabolism	metabolism	B-NP	NN	O	22	PMOD	0
24	.	.	O	.	O	3	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	results	result	I-NP	NNS	O	3	SUB	0
3	show	show	B-VP	VBP	O	0	ROOT	-1
4	that	that	B-SBAR	IN	O	3	VMOD	-1
5	STX243	STX243	B-NP	NN	B-protein	6	SUB	-1
6	is	be	B-VP	VBZ	O	4	SBAR	-1
7	a	a	B-NP	DT	O	11	NMOD	-1
8	potent	potent	I-NP	JJ	O	11	NMOD	-1
9	in	in	I-NP	FW	O	10	AMOD	-1
10	vivo	vivo	I-NP	FW	O	11	NMOD	-1
11	drug	drug	I-NP	NN	O	6	PRD	-1
12	and	and	O	CC	O	3	VMOD	-1
13	could	could	B-VP	MD	O	3	VMOD	-1
14	be	be	I-VP	VB	O	13	VC	-1
15	clinically	clinically	B-ADJP	RB	O	16	AMOD	-1
16	effective	effective	I-ADJP	JJ	O	14	PRD	0
17	at	at	B-PP	IN	O	14	VMOD	-1
18	treating	treat	B-VP	VBG	O	17	PMOD	0
19	a	a	B-NP	DT	O	20	NMOD	-1
20	number	number	I-NP	NN	O	18	OBJ	-1
21	of	of	B-PP	IN	O	20	NMOD	-1
22	oncological	oncological	B-NP	JJ	O	23	NMOD	-1
23	conditions	condition	I-NP	NNS	O	21	PMOD	-1
24	.	.	O	.	O	3	P	-1

